Beam Therapeutics

Website:beamtx.com
Location:Boston, MA United States
Revenue:N/A
Industry:Biotech
Founded:2017
Lead Investor(s):Muliteple
Press

Current Growjo Ranking

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Beam Therapeutics is developing precision genetic medicines for serious diseases. Co-founded by scientific pioneers known for advancing CRISPR gene editing, we?re the first company to pursue development of new therapies using CRISPR base editing technology. We aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. WHO WE ARE Beam is creating precision genetic medicines through base editing WHY WE DO IT Our dream is to provide life-long cures for patients suffering from serious diseases WHO WE ARE AND HOW WE WORK TOGETHER The Beam Team: ? A community of fearless innovators ? Rigorous and honest in our research ? Listening with open minds ? Committed to each other

keywords:N/A

66

Number of Employees

N/A

Revenue (est)

13

Current Jobs

267%

Employee Growth %

$222M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Beam Therapeutics News

6-Mar-19 - Beam Brings In $135M to Turn CRISPR Base Editing into Drugs

Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR

7-Mar-19 - Single-letter gene editing startup Beam Therapeutics raises $135M

Cambridge, Massachusetts-based Beam Therapeutics said Wednesday that it had closed a $135 million Series B funding round.

7-Mar-19 - Beam Therapeutics secures $135m funds to expand pipeline of

Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, announced the successful

Beam Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-05-15$87.0MAF-Prime Capital PartnersArticle
2019-03-07$135.0MBMulitepleArticle